Celularity

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.

Earnings

News

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

CELU

WDAY

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Workday, Domino&#39;s And 3 Stocks To Watch Heading Into Monday

Eurozone

Commodities

Small Cap

Global

Intraday Update

CMPR

NRBO

PTON

REVB

VLCN

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 250 points on Thursday.

The Dow traded up 0.66% to 38,403.91 while the NASDAQ rose 1.01% to 15,316.80. The S&amp;P 500 also rose, gaining, 0.87% to 4,887.70.

Dow Jumps 250 Points; Honeywell Issues Weak Forecast

Movers

ALGM

ASST

BFRG

BOOT

BRTX

CACC

CHRW

CMAX

CMND

CTVA

DGII

EGHT

ELAB

ELWS

ETSY

EVAX

EVER

FBLG

FCEL

HSAI

IFBD

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

MINM

NVIV

NYCB

OGEN

PLUG

PSNY

RACE

RKLB

SPWR

SRDX

TCRT

WOLF

YOSH

ZION

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.

Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Celularity Inc

Press Releases

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

General

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Celularity Inc. Announces Receipt of Nasdaq Notification

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Health Care

MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

Analyst Ratings

Celularity Announces Publication of "Senescence, NK cells, and cancer: navigating the crossroads of aging and disease" in the April 4, 2025, Issue of Frontiers in Immunology

CELUW

Aligos Therapeutics

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

CytomX Therapeutics

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroBiologics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

iBio

MiNK Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Kezar Life Sciences

Lantern Pharma

PepGen

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Rein Therapeutics

RenovoRx

Spero Therapeutics

Surrozen

Shattuck Labs

X4 Pharmaceuticals

Xilio Therapeutics

Morgan Stanley

HC Wainwright & Co.

Alliance Global Partners

Truist Securities

Comments

Celularity

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga